Antisense Therapeutics Limited Stock Probability of Future Pink Sheet Price Finishing Over 39.76
| ATHJF Stock | USD 0.04 0.00 0.00% |
Antisense |
Antisense Therapeutics Target Price Odds to finish over 39.76
The tendency of Antisense Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 39.76 or more in 90 days |
| 0.04 | 90 days | 39.76 | close to zero percent |
Based on a normal probability distribution, the odds of Antisense Therapeutics to move over $ 39.76 or more in 90 days from now is close to zero percent (This Antisense Therapeutics Limited probability density function shows the probability of Antisense Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Antisense Therapeutics price to stay between its current price of $ 0.04 and $ 39.76 at the end of the 90-day period is about 41.78 .
Assuming the 90 days horizon the pink sheet has the beta coefficient of 7.4 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Antisense Therapeutics will likely underperform. In addition to that Antisense Therapeutics Limited has an alpha of 3.6746, implying that it can generate a 3.67 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Antisense Therapeutics Price Density |
| Price |
Predictive Modules for Antisense Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Antisense Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Antisense Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Antisense Therapeutics is not an exception. The market had few large corrections towards the Antisense Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Antisense Therapeutics Limited, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Antisense Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 3.67 | |
β | Beta against Dow Jones | 7.40 | |
σ | Overall volatility | 0.02 | |
Ir | Information ratio | 0.11 |
Antisense Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Antisense Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Antisense Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Antisense Therapeutics is way too risky over 90 days horizon | |
| Antisense Therapeutics has some characteristics of a very speculative penny stock | |
| Antisense Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 1.78 M. Net Loss for the year was (5.81 M) with profit before overhead, payroll, taxes, and interest of 1.71 M. | |
| Antisense Therapeutics Limited has accumulated about 19.23 M in cash with (7.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03. | |
| Roughly 19.0% of the company shares are held by company insiders |
Antisense Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Antisense Pink Sheet often depends not only on the future outlook of the current and potential Antisense Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Antisense Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 668.8 M | |
| Shares Float | 532.6 M |
Antisense Therapeutics Technical Analysis
Antisense Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Antisense Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Antisense Therapeutics Limited. In general, you should focus on analyzing Antisense Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Antisense Therapeutics Predictive Forecast Models
Antisense Therapeutics' time-series forecasting models is one of many Antisense Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Antisense Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Antisense Therapeutics
Checking the ongoing alerts about Antisense Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Antisense Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Antisense Therapeutics is way too risky over 90 days horizon | |
| Antisense Therapeutics has some characteristics of a very speculative penny stock | |
| Antisense Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 1.78 M. Net Loss for the year was (5.81 M) with profit before overhead, payroll, taxes, and interest of 1.71 M. | |
| Antisense Therapeutics Limited has accumulated about 19.23 M in cash with (7.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03. | |
| Roughly 19.0% of the company shares are held by company insiders |
Other Information on Investing in Antisense Pink Sheet
Antisense Therapeutics financial ratios help investors to determine whether Antisense Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antisense with respect to the benefits of owning Antisense Therapeutics security.